Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Following the previous information on June 30th in 2023, we are excited to share our latest development status.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, January 5, 2024
Information
Tags: 
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, PEGylation, PEG, Cancer, Patent, VTX, Patient, Acute myeloid leukemia, ADC, AML, Pharmaceutical industry
Geotags: 
UNITED STATES, UNITED KINGDOM, CANADA, JAPAN, NORTH AMERICA, ASIA PACIFIC, EUROPE, PK, TAIWAN, US
⚠ partially generated by AI ↴
Organisation: 
DELTA-FLY PHARMA, DELTA-FLY PHARMA, INC.
Stock Symbol: 
TOKYO:4598
Summary
Key Points: 
  • Following the previous information on June 30th in 2023, we are excited to share our latest development status.
  • A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing of the interim analysis.
  • A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.
  • Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.


Following the previous information on June 30th in 2023, we are excited to share our latest development status.

  1. A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing of the interim analysis.
  2. A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.
  3. A patent has been granted in the U.S. for the combination therapy of DFP-10917 and VTX based on the animal study’s data by using of animal model of AML in addition to Japan and Taiwan.
  4. Pharmacology studies of DFP-14927, which is a 4 arm PEG conjugate of DFP-10917 by amido bond, can be selectively activated by the amidase activity of protease highly expressed in the tumor, is ongoing at a major university in the US for a Phase I/II study of DFP-14927 in the patients with R/R AML.
  5. A Phase I study of DFP-14927 in the patients with advanced solid cancers in the US has been completed with an extraordinary safe profile and also long stable diseases over 5 months in the three patients in advance for the next expansion study, which likes early Phase II study. The PK profile of DFP-10917 (active form) in the tumors of the cancer patients treated with DFP-14927 is under investigation for establishing of the good relationship with efficacy to confirm a useful drug delivery system likes ADC (antibody-drug conjugate).
  6. Both the patents of PEGylated VTX and DFP-14927 have been granted in worldwide, and their pharmacological data have been published in the leading oncology journals.

Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.

Copyright: 
Copyright Business Wire 2024